Valneva SE (NASDAQ:VALN - Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 2,390,903 shares were traded during trading, an increase of 6,483% from the previous session's volume of 36,322 shares.The stock last traded at $6.16 and had previously closed at $6.04.
Analyst Ratings Changes
A number of research firms recently weighed in on VALN. Guggenheim lowered their price objective on shares of Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, March 24th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Wednesday, April 9th.
Check Out Our Latest Analysis on VALN
Valneva Trading Up 12.1 %
The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business has a 50 day moving average price of $6.98 and a 200-day moving average price of $5.62. The firm has a market capitalization of $572.89 million, a PE ratio of -54.23 and a beta of 1.85.
Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The business had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Analysts expect that Valneva SE will post 0.13 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC acquired a new stake in shares of Valneva during the 1st quarter valued at approximately $94,000. Wells Fargo & Company MN increased its stake in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares in the last quarter. Finally, ABC Arbitrage SA acquired a new position in Valneva during the fourth quarter worth $84,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Recommended Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
